SuperworthQ32 Bio PE ratio QTTB
Share price divided by earnings per share over the last twelve months, since 2017.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Earnings per share, 12 months
- $65.93
- to Sep 30, 2024
- Share price
- $8.65
- Oct 23, 2026
- Peer median
- 11.3×
Q32 Bio's PE ratio is not a meaningful number today: diluted EPS for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2023 | −$1.91 | n/a |
| FY2022 | −$1.98 | n/a |
| FY2021 | −$30.42 | n/a |
| FY2020 | −$50.40 | n/a |
| FY2019 | −$44.46 | n/a |
| FY2018 | −$95.76 | n/a |
| FY2017 | −$229.32 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.44 | n/a | n/a | |
| Q1 FY26 | −$0.54 | n/a | n/a | |
| Q3 FY25 | −$0.60 | n/a | n/a | |
| Q2 FY25 | −$0.78 | n/a | n/a | |
| Q1 FY25 | −$0.90 | n/a | n/a | |
| Q3 FY24 | −$1.46 | n/a | $65.93 | |
| Q2 FY24 | −$1.42 | n/a | $26.87 | |
| Q1 FY24 | −$6.33 | n/a | $11.60 | |
| Q4 FY23 | $75.14 | n/a | −$1.91 | |
| Q3 FY23 | −$40.52 | n/a | −$87.85 | |
| Q2 FY23 | −$16.69 | n/a | −$57.95 | |
| Q1 FY23 | −$19.84 | −169% | −$50.44 |
Against its peers
Companies in Drug Manufacturers - General nearest Q32 Bio's size, closest first, today.
| Company | PE ratio |
|---|---|
| QTTBQ32 Bio | n/m |
| NATRNatures Sunshine Products | 12.0× |
| ARVNArvinas | 45.6× |
| PBYIPuma Biotechnology | 21.2× |
| IRWDIronwood Pharmaceuticals | 4.5× |
| ZVRAZevra Therapeutics | 10.5× |
| CRMDCorMedix | 3.7× |
| COLLCollegium Pharmaceutical | 18.5× |
| ABUSArbutus Biopharma | 5.4× |
| LFVNLifevantage | 14.7× |
| SPROSpero Therapeutics | 10.1× |
| Peer median | 11.3× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Q32 Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.